JP Morgan Chase’s Lucid Diagnostics LUCD Stock Holding History
Bought
Maintained
Sold
Other funds holding LUCD
TSC
MCM
JP Morgan Chase's LUCD Position: Q2 2026 in Review
JP Morgan Chase increased its Lucid Diagnostics (LUCD) stake by 13% in Q2 2026, buying an estimated $7.68K and bringing the position to 62,775 shares worth $65.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6301.
JP Morgan Chase first reported a position in LUCD in Q4 2021 and has held it in 15 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.
- JP Morgan Chase held 62,775 shares of Lucid Diagnostics worth $65.9K as of Q2 2026.
- JP Morgan Chase bought 7,127 Lucid Diagnostics shares in Q2 2026, an estimated $7.68K.
- Lucid Diagnostics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6301 holding.
- JP Morgan Chase first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 15 quarters since.
- 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.